BIND Therapeutics Appoints Andrew Hirsch as Acting President and Chief Executive Officer

BIND Therapeutics Appoints Andrew Hirsch as Acting President and Chief Executive Officer

March 10, 2015

- Additional organization changes and key hires further strengthen BIND leadership team -

- Scott Minick returns to career on West Coast after five years in leadership role -

Eleven Biotherapeutics Reports Fourth Quarter and Year-End 2014 Financial Results

Eleven Biotherapeutics Reports Fourth Quarter and Year-End 2014 Financial Results

March 4, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2014.

Quanterix Expands Kevin Hrusovsky’s Role to CEO

Quanterix Expands Kevin Hrusovsky’s Role to CEO

March 4, 2015

Life Science and Diagnostics Veteran to lead Quanterix in Driving Growth of its Disruptive Technology

Quanterix Corporation (“Quanterix”), a leader in ultrasensitive single molecule measurement for the benefit of human health, today announced the appointment of Kevin Hrusovsky as Chief Executive Officer (“CEO”). Mr. Hrusovsky will continue to serve as Executive Chairman of its Board of Directors.

Acceleron Presents Encouraging Response Rates and Progression-Free Survival Data in Patients with Advanced Renal Cell Carcinoma at the American Society of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium

Acceleron Presents Encouraging Response Rates and Progression-Free Survival Data in Patients with Advanced Renal Cell Carcinoma at the American Society of Clinical Oncology (ASCO) 2015 Genitourinary Cancers Symposium

February 28, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today reported new preliminary data from the DART study, an ongoing phase 2 clinical trial of dalantercept in patients with advanced renal cell carcinoma (RCC).

Acceleron Pharma Reports Fourth Quarter and Year Ended 2014 Financial and Operational Results

Acceleron Pharma Reports Fourth Quarter and Year Ended 2014 Financial and Operational Results

March 2, 2015

- Phase 2 data from luspatercept trials in β-thalassemia and MDS patients given as oral presentations at ASH and MDS abstract included in "Best of ASH" session -

- Plans with Celgene to initiate phase 3 clinical trials in both β-thalassemia and MDS in 2015 -

- Sotatercept slowed the progression of vascular calcification in patients with end stage kidney disease -

Acceleron Pharma Announces Executive Appointments and Promotions

Acceleron Pharma Announces Executive Appointments and Promotions

March 6, 2015

- Steven Ertel named Executive Vice President and Chief Operating Officer -

- Matthew Sherman, M.D. named Executive Vice President and Chief Medical Officer -

Editas Medicine Reports New Data Demonstrating Potential of CRISPR/Cas9 Construct as Novel Gene Repair Mechanism

Editas Medicine Reports New Data Demonstrating Potential of CRISPR/Cas9 Construct as Novel Gene Repair Mechanism

March 2, 2015

Oral presentation at Keystone Symposium for Genomic Instability and DNA Repair Highlights Potential for Use in Sickle Cell Anemia Mutation

Joule Receives Prestigious Frost & Sullivan Technology Innovation Award

Joule Receives Prestigious Frost & Sullivan Technology Innovation Award

March 2, 2015

Bedford, Mass. – Joule, the pioneer of direct, solar recycling of CO2-to-liquid fuels, announced today that its platform was awarded the 2015 Technology Innovation Award by Frost & Sullivan. The award, which recognizes organizations addressing unique and critical challenges, was presented to Joule for its ability to recycle waste carbon dioxide (CO2) into drop-in liquid fuels using sunlight.

FDA Advisory Committee Recommends Approval for Avedro’s Riboflavin Ophthalmic Solutions with UVA Irradiation for Corneal Collagen Cross-Linking to Treat Progressive Keratoconus and Corneal Ectasia

FDA Advisory Committee Recommends Approval for Avedro’s Riboflavin Ophthalmic Solutions with UVA Irradiation for Corneal Collagen Cross-Linking to Treat Progressive Keratoconus and Corneal Ectasia

February 27, 2015

Avedro, Inc., a Boston-based ophthalmic pharmaceutical and medical device company, announced today that on February 24, 2015 the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee and Ophthalmic Devices Panel of the Medical Devices Advisory Committee voted in support of approval for Avedro’s new drug application (NDA) for riboflavin ophthalmic solutions with UVA irradiation for use in corneal collagen cross-linking for the treatment of the conditions underlying progressive keratoconus or corneal ectasia following refractive surgery.

Concert Pharmaceuticals Reports Year End 2014 Financial Results

Concert Pharmaceuticals Reports Year End 2014 Financial Results

February 27, 2015

Conference Call Scheduled Today at 8:30 a.m. ET